Advertisement

Topics

Companies Related to "Assessing Risk Stratification Across Pivotal Prostate Cancer Trials" [Most Relevant Company Matches] RSS

16:15 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Assessing Risk Stratification Across Pivotal Prostate Cancer Trials" found in our extensive corporate database of over 50,000 company records.

Showing "Assessing Risk Stratification Across Pivotal Prostate Cancer Trials" Companies 1–25 of 4,400+

Extremely Relevant

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.


Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...

The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer at every stage of diagnosis. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 instit...


Cellanyx Diagnostics

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor ...

Relevant

Stratify Genomics, Inc.

Currently, there are 35,000 men annually who are unaware of a curable form of clinically significant prostate cancer. Relying solely on family history, 80% of prostate cancer cases would be missed. The most common screening tool, prostate-specific antigen (PSA) testing, has declined in usage due to controversial guidelines, which has led to a significant i...

Prostate Oncology Specialists, Inc.

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.

YM BioSciences

YM BioSciences is a product development company. Our focus is to advance cancer products along the regulatory and clinical pathways towards commercial approval. YMB does not conduct basic research; rather, our product portfolio is established through a process of careful, rational selection of therapeutics produced in research institutions around the globe. We have one of the broadest oncology po...

GTX

GTx, Inc., headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel hormonal therapeutics for cancer and serious conditions related to men’s health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx is developing...

AEterna Laboratories Incorporated

Æterna Laboratories Inc. is a biopharmaceutical company focused on the treatment of cancer. The company’s lead product, Neovastat®, is the focus of a number of clinical trials including pivotal trials for the treatment of lung and kidney cancer, and multiple myeloma, a type of blood cancer.

Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop an...

Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® ...

Signet Laboratories Incorporated

Signet Laboratories, Inc is a medical biotechnology company focused in fields of cancer and infectious disease(Sepsis). Signet has developed proprietary antibody systems for the detection and management of breast and prostate cancer and Sepsis. Signet's patented technology will provide for determining risk in "normal patients who may be at increased risk for developing cancer at a time when proac...

RC Cancer Centers

Each year thousands of patients from around the world and across the United States turn to RC Cancer Centers seeking a cure for their prostate cancer and learn why they are The Choice for Saving Lives. Founded in 1979, Radiotherapy Centers of Georgia, a division of RC Cancer Centers, has earned a reputation for being one of the country's top cancer treatment and research facilities because of its ...

Prostate Oncology Specialists,Inc.

Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer. We have vast experience diagnosing and treating prostate cancer because 100% of our time is focused on managing men with this disease. Our physicians are board certified in both medical oncology and internal medicine and have made significant contributions to the scientific advancement in t...

Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company specialising in therapeutics and diagnostics for prostate cancer and other cancers. Minomic has developed the in vitro diagnostic test called MiCheck® for the early detection of prostate cancer. Minomic is preparing to globally launch its first product, a novel prostate cancer blood test...

MetaStat, Inc.

MetaStat, Inc (OTCQB:MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where syst...

Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF; CNSX: PVO) specialty pharmaceutical company with a focus on cardiovascular and overall health. Pivotal Therapeutics' lead product VASCAZENTM is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients ...

Coalition to Cure Prostate Cancer

The Coalition to Cure Prostate Cancer is a philanthropic organization that funds and accelerates advanced prostate cancer research in Canada. Beginning in 2011, the Coalition has identified unique strategies to invest in the most promising research programs that generate life-saving results. By channeling resources to Canada’s top scientific minds, red ...

Glactone Pharma AB

Glactone Pharma AB is developing a drug for the treatment of castration resistant prostate cancer. Research has shown that the natural product galiellalactone can modulate a signaling protein (STAT3) that is over activated in cancer cells. The goal is to develop drugs against metastasizing cancer where galiellalactone is used as a chemical starting point to make new novel, patentable compounds. ...

Tokai Pharmaceuticals

Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, TOK-001, is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic....

Cancer Trials Australia

Cancer Trials Australia is the leading provider of early phase cancer clinical trials because we aim for excellence in quality, timeliness and cost. We will achieve our vision by sustaining a collaborative culture, protecting our outstanding reputation, and actively encouraging innovation.Cancer Trials Australia is a not-for-profit service organisation that operates with the highest standards of e...

VitreosHealth

VitreosHealth®, an innovative provider of predictive population risk analytics for care management and contract optimization leverages EMR, Claims & Demographics data for medical homes, physician groups, ACOs, hospital systems, IDNs, and shared savings programs. VitreosHealth® with its “ACO-in-a-Box” and “PCMH-in-a-Box” solutions deliver...

Coagulation Diagnostics Incorporated

Coagulation Diagnostics, Inc. (CDI) develops proprietary diagnostic tests for hypercoagulability, or the tendency to form blood clots. The primary applications for the Company's diagnostic tests include monitoring of novel anticoagulants, assessing the risk of acute myocardial infarction, diagnosing possible reactivation of ischemia, and assessing the risk of clotting following invasive cardiovasc...

ImmunSYS, Inc.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas. The company’s platform technology, YourVaccx™ utilizes a novel combination of the proprietary ANTIGENerator™ energ...

Ipsogen, Inc

Ipsogen foresees cancer, the second leading cause of death in developed countries, as a unique domain where drug development, commercialisation and prescription can benefit from biomarker discovery, validation and use as companion diagnostics:• Cancer patients require accurate assessment of their disease to optimise the use of existing drugs and to access new innovative targeted therapies.• On...


More From BioPortfolio on "Assessing Risk Stratification Across Pivotal Prostate Cancer Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks